Tegaserod
As of the edition of 20 October 2026, Tegaserod is a small molecule: withdrawn from the market in 2007; acts on HTR4; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 2007
- Kind
- Small molecule
- Brand name
- Zelnorm
- First approved
- 24 July 2002 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Alfasigma
- Withdrawn from market
- 1 January 2007 (in some regions)
- Registered trials
- 25, 9 stopped early
- Disease areas
- Digestive system; Chemically induced; Mental health; Hormones; Nutrition and metabolism
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Tegaserod.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HTR4 | 5-hydroxytryptamine receptor 4 | Q13639 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 0 | 0 | 1 |
| Phase 2 | 2 | 1 | 0 | 1 |
| Phase 3 | 14 | 10 | 0 | 4 |
| Phase 4 | 6 | 3 | 0 | 3 |
| All trials | 25 |